Opportunity Information: Apply for PAR 10 282
Apply for PAR 10 282
- The National Institutes of Health in the health sector is offering a public funding opportunity titled "Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846 Arthritis, Musculoskeletal and Skin Diseases Research.
- This funding opportunity was created on Sep 16, 2010 and posted on Sep 16, 2010.
- Applicants must submit their applications by Jul 1, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: Special district governments Native American tribal governments (Federally recognized) Others (see text field entitled Additional Information on Eligibility for clarification) Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Small businesses State governments Public and State controlled institutions of higher education County governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education City or township governments For profit organizations other than small businesses Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments).
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) opportunity (Funding Opportunity Number PAR-10-282) is a National Institutes of Health program run through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Its main goal is to support early stage, exploratory clinical research that looks at preventing or treating arthritis, musculoskeletal diseases, and skin diseases, as well as related conditions or injuries. The emphasis is on short term clinical studies that help researchers try out promising new ideas without having to meet the heavier preliminary data expectations that are typical for larger, later phase clinical trials. In practical terms, NIAMS is trying to create space for researchers to test whether a concept is clinically workable, safe enough to pursue further, and worth scaling into a more definitive, full clinical trial later on.
A central theme of the program is generating the kind of critical preliminary evidence that can justify and shape a future planned clinical trial. Projects under this FOA are expected to ask focused clinical questions and to collect data that reduces uncertainty for the next step, such as feasibility of recruitment and retention, acceptability of an intervention, appropriate outcome measures, early signals of biological or clinical effect, adherence and dosing considerations, or whether a proposed protocol can be implemented as designed. The announcement specifically notes that studies may include testing new treatment approaches or prevention strategies, evaluating a new intervention, or assessing novel combinations of therapies. NIAMS also highlights translation as a high priority, meaning they want these pilot efforts to help move strong laboratory or preclinical developments toward real world clinical testing and, ultimately, clinical practice if the evidence supports it.
This funding uses the NIH R21 Exploratory/Developmental grant mechanism, which is designed for exploratory work that is innovative and potentially high impact, but not yet supported by extensive preliminary results. The R21 structure aligns with the program intent: shorter, more targeted studies meant to answer key early questions rather than to serve as the final, definitive test of efficacy. While the FOA text provided does not spell out the exact project period, the R21 mechanism is generally understood as a time limited award intended for early development and proof of concept activities, and NIAMS frames these as short term clinical studies specifically.
Financially, the listed award ceiling is $200,000. The announcement also makes clear that the actual size and duration of each award may vary because the scope of proposed projects can differ widely, and NIAMS expects that variability. There is no cost sharing or matching requirement. The total amount NIAMS ultimately awards and the number of awards it makes are not fixed in the summary and instead depend on the number of applications received and, importantly, their quality, duration, and cost. The funding activity category is Health, and the CFDA number associated with this program is 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).
Eligibility is broad and includes many types of applicant organizations. Eligible applicants listed include state, county, city or township governments; special district governments; public and state controlled institutions of higher education; private institutions of higher education; independent school districts; nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits outside of higher education); for profit organizations (including small businesses and other for profits); public housing authorities and Indian housing authorities; and a wide range of tribal entities, including federally recognized tribal governments and other tribal organizations. The eligibility section also notes additional categories such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith based or community based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and non U.S. entities (foreign organizations). In short, NIAMS structured this FOA so that universities, research institutes, nonprofits, governments, and other qualified organizations can all compete, including entities that serve historically underrepresented or special populations.
From an administrative standpoint, the opportunity was posted and created on September 16, 2010, with an original closing date of July 1, 2013 and a current closing date also listed as July 1, 2013. The archive date is August 1, 2013. That means the specific announcement as written is historical and no longer open, but it still reflects NIAMS priorities and a model for how NIH uses R21s to seed pilot clinical research. The primary online reference for the full announcement is the NIH Grants Guide page at http://grants.nih.gov/grants/guide/pa-files/PAR-10-282.html, and the contact provided for access or linking problems is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, this FOA is best understood as a bridge between discovery and definitive clinical testing: it funds small, carefully designed clinical studies that are meant to de risk a future clinical trial by producing early human data, refining protocols, and demonstrating feasibility, with a strong preference for work that helps translate promising scientific advances into approaches that can eventually improve prevention and treatment in arthritis, musculoskeletal, and skin disease care.
Frequently Asked Questions (FAQs)
What is this grant opportunity?
This is the Pilot and Feasibility Clinical Research Grants in Arthritis and Musculoskeletal and Skin Diseases (R21) funding opportunity from the National Institutes of Health (NIH), administered through the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The Funding Opportunity Number is PAR-10-282.
What is the main purpose of PAR-10-282?
The main goal is to support early stage, exploratory clinical research focused on preventing or treating arthritis, musculoskeletal diseases, and skin diseases, as well as related conditions or injuries. The program is designed to help researchers test promising new clinical ideas in a short-term format, without needing the extensive preliminary data typically expected for larger, later-phase clinical trials.
What type of studies does NIAMS want to fund through this program?
NIAMS emphasizes short-term clinical studies that answer focused clinical questions and generate preliminary evidence to justify and shape a future planned clinical trial. Examples mentioned in the opportunity include testing new treatment approaches or prevention strategies, evaluating a new intervention, or assessing novel combinations of therapies.
What does "pilot and feasibility" mean in this FOA?
In this context, "pilot and feasibility" refers to clinical research designed to reduce uncertainty before launching a larger, definitive clinical trial. Projects are expected to collect data that helps determine whether a proposed clinical concept is workable and worth scaling up.
What kinds of preliminary evidence are projects expected to generate?
The announcement highlights generating preliminary data that can support the next step (a planned clinical trial). The types of evidence specifically called out include:
- Feasibility of recruitment and retention
- Acceptability of an intervention
- Selection of appropriate outcome measures
- Early signals of biological or clinical effect
- Adherence and dosing considerations
- Whether the proposed protocol can be implemented as designed
Is the focus on definitive efficacy trials or early-stage exploratory work?
The focus is on early-stage exploratory work. These studies are intended to answer key early clinical questions and support future trial planning, rather than serve as the final, definitive test of efficacy.
What grant mechanism is used for this opportunity?
This funding uses the NIH R21 Exploratory/Developmental grant mechanism, which supports innovative, potentially high-impact exploratory projects that do not yet have extensive preliminary results.
How does the R21 mechanism fit the goals of this program?
The R21 mechanism aligns with the intent to fund shorter, more targeted clinical studies that establish proof of concept and feasibility, helping investigators prepare for a larger and more definitive clinical trial later.
What disease areas are covered?
The FOA targets clinical research related to arthritis, musculoskeletal diseases, and skin diseases. It also notes related conditions or injuries within this scientific and clinical scope.
Is translation from lab or preclinical research to clinical testing encouraged?
Yes. The opportunity notes that translation is a high priority, meaning NIAMS wants pilot clinical efforts that help move strong laboratory or preclinical developments toward real-world clinical testing and, if supported by evidence, toward clinical practice.
What is the maximum award amount listed for this FOA?
The listed award ceiling is $200,000.
Are cost sharing or matching funds required?
No. The announcement states there is no cost sharing or matching requirement.
Will all awards have the same size and duration?
No. The opportunity notes that award size and duration may vary because project scopes can differ widely, and NIAMS expects that variability.
Is the project period specified in the provided FOA summary?
The provided text does not spell out the exact project period. It notes, however, that the R21 mechanism is generally understood as time-limited and NIAMS frames these projects as short-term clinical studies.
How many awards will NIAMS make under this program?
The total number of awards is not fixed in the summary. It depends on the number of applications received and their quality, duration, and cost.
What is the funding activity category and CFDA number?
The funding activity category is Health. The CFDA number associated with this program is 93.846 (Arthritis, Musculoskeletal and Skin Diseases Research).
Who is eligible to apply?
Eligibility is broad. The opportunity lists many eligible applicant types, including:
- State, county, city, or township governments
- Special district governments
- Public and state controlled institutions of higher education
- Private institutions of higher education
- Independent school districts
- Nonprofit organizations (including 501(c)(3) and certain non-501(c)(3) nonprofits outside of higher education)
- For-profit organizations (including small businesses and other for-profits)
- Public housing authorities and Indian housing authorities
- Tribal entities (federally recognized tribal governments and other tribal organizations)
Are organizations serving specific populations explicitly included as eligible?
Yes. The eligibility section also mentions categories such as Alaska Native and Native Hawaiian Serving Institutions, Hispanic Serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), as well as faith-based or community-based organizations.
Are U.S. territories or non-U.S. entities eligible?
Yes. The eligibility section includes U.S. territories or possessions and non-U.S. entities (foreign organizations). It also includes eligible federal agencies and regional organizations.
Is this funding opportunity currently open?
No. Based on the provided dates, this specific announcement is historical. It was posted on September 16, 2010, lists a closing date of July 1, 2013 (also shown as the current closing date), and has an archive date of August 1, 2013.
Where can applicants or interested parties find the full announcement?
The primary online reference provided is the NIH Grants Guide page: http://grants.nih.gov/grants/guide/pa-files/PAR-10-282.html
Who should be contacted for access or linking problems with the NIH page?
The contact listed for access or linking problems is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
How should this FOA be understood in the broader research pipeline?
It is positioned as a bridge between discovery and definitive clinical testing. It supports small, carefully designed clinical studies intended to de-risk a future clinical trial by producing early human data, refining protocols, and demonstrating feasibility, particularly for work that translates promising scientific advances into potential clinical approaches for arthritis, musculoskeletal, and skin diseases.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Health
Next opportunity: New Bedford Whaling NHP Seamen s Bethel Restoration
Previous opportunity: National Historic Preservation
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 10 282
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 10 282) also looked into and applied for these:
| Funding Opportunity |
|---|
| Ryan White Part B Supplemental Apply for HRSA 11 099 Funding Number: HRSA 11 099 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Institute on Aging Revision Requests for Active Program Projects (P01) Apply for PAR 10 284 Funding Number: PAR 10 284 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Alliance for Information on Maternal and Child Health (AIM) Cooperative Agreement Program Apply for HRSA 11 111 Funding Number: HRSA 11 111 Agency: Health Resources and Services Administration Category: Health Funding Amount: $200,000 |
| Universal Newborn Hearing Screening and Intervention Apply for HRSA 11 039 Funding Number: HRSA 11 039 Agency: Health Resources and Services Administration Category: Health Funding Amount: $300,000 |
| NHLBI Program Project Applications (P01) Apply for PAR 10 285 Funding Number: PAR 10 285 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Strengthen and Improve the Nation s Capacity through National, Non profit, Professional Public Health Organizations to Increase Health Protection and Health Equity Apply for CDC RFA HM08 8050302SUPP10 Funding Number: CDC RFA HM08 8050302SUPP10 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $980,000 |
| SUID/SIDS Prevention and Bereavement Support Resource Centers Apply for HRSA 11 104 Funding Number: HRSA 11 104 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Diagnosis and Management of Severe Febrile Illness Apply for USAID TANZANIA 10 011 RFA Funding Number: USAID TANZANIA 10 011 RFA Agency: Tanzania USAID Dar es Salaam Category: Health Funding Amount: $24,000,000 |
| International AIDS Education and Training Center Apply for HRSA 11 063 Funding Number: HRSA 11 063 Agency: Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Clinical and Data Coordinating Center(s) for Parkinsons Disease Biomarkers Identification Network (PD BIN) (U01) Apply for RFA NS 11 005 Funding Number: RFA NS 11 005 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| National Mentoring Networks to Enhance the Clinician Investigator Workforce in Deafness and Other Communication Disorders (U24) Apply for RFA DC 11 001 Funding Number: RFA DC 11 001 Agency: National Institutes of Health Category: Health Funding Amount: $250,000 |
| NHLBI Translational Research Implementation Program (TRIP) Limited Competition (P50) Apply for RFA HL 12 003 Funding Number: RFA HL 12 003 Agency: National Institutes of Health Category: Health Funding Amount: $1,515,000 |
| NIMH Research Education Programs for HIV/AIDS Research (R25) Apply for PAR 11 002 Funding Number: PAR 11 002 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Domestic Violence Prevention Enhancement Leadership Through Allianc (DELTA) III Apply for CE09 90103CONT11 Funding Number: CE09 90103CONT11 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: Case Dependent |
| Affordable Care Act (ACA) Grants for School Based Health Centers Capital (SBHCC) Program Apply for HRSA 11 127 Funding Number: HRSA 11 127 Agency: Health Resources and Services Administration Category: Health Funding Amount: $500,000 |
| Epidemiolgic and Ecologic Determinants of Monkeypox in a Disease endemic Setting Apply for RFA CK 11 003 Funding Number: RFA CK 11 003 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $500,000 |
| NIH Directors Early Independence Awards (DP5) Apply for RFA RM 10 019 Funding Number: RFA RM 10 019 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01) Apply for PAR 11 003 Funding Number: PAR 11 003 Agency: National Institutes of Health Category: Health Funding Amount: Case Dependent |
| NIDCD Research Grants for Translating Basic Research into Clinical Tools (R21) Apply for PAR 11 004 Funding Number: PAR 11 004 Agency: National Institutes of Health Category: Health Funding Amount: $200,000 |
| Sexually Transmitted Diseases/Human Immunodeficiency Virus Prevention Training Centers Apply for CDC RFA PS11 1103 Funding Number: CDC RFA PS11 1103 Agency: Centers for Disease Control and Prevention Category: Health Funding Amount: $3,662,737 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 10 282", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.